Research Summary

Analyzed using Evidence Intelligence™

Dapagliflozin improves metabolic outcomes in type 2 diabetes patients

Key finding

The dapagliflozin group showed significant decreases in BMI.

This study compared the effects of dapagliflozin and vitamin E in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, finding significant improvements in several metabolic parameters with dapagliflozin.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Some Concerns bias

Last updated July 6, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Dapagliflozin

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Primary outcome

Serum AST

Comparator

Vit E group

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

Clinical relevance

This study highlights the potential of dapagliflozin as a more effective treatment option for patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, which could lead to better management of these conditions and improved patient outcomes.

Keep in mind

Intergroup differences in liver enzyme reductions were not significant. No changes were observed in type IV collagen levels. The study may have limited generalizability due to specific population characteristics.

Published in

Journal Reference

Publication details and source links for this paper.

Hiroo F, Kazuyoshi K, Reiko Y, et al. Dapagliflozin versus Vitamin E in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes: A Randomized Controlled Trial. Frontiers in Medicine. 2025;12:1542741. doi:10.3389/fmed.2025.1542741

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

Dapagliflozin group showed significant decreases in BMI.

Dapagliflozin group showed significant decreases in HbA1c.

Dapagliflozin group showed significant decreases in LDL cholesterol.

Both groups demonstrated significant reductions in serum AST and ALT levels.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Dapagliflozin and AST, Alanine Aminotransferase (ALT), BMI, and 8 more.

This study contributes evidence to

Intervention

Dapagliflozin

Outcome

AST

Evidence topic

Weight Loss

Primary intervention

Dapagliflozin

Primary outcomes

AST
Alanine Aminotransferase (ALT)
BMI

Evidence topics

Weight Loss HbA1c Reduction SGLT2 Inhibitors

Primary intervention

Dapagliflozin

Primary outcomes

AST Alanine Aminotransferase (ALT)BMI

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 11 evidence relationships
Includes primary outcome data
Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Dapagliflozin → Type IV collagen

Evidence profile

NoneNo ChangeMetabolic Health

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

Dapagliflozin significantly reduced BMI and HbA1c levels.
Both treatments reduced serum AST and ALT, but dapagliflozin had superior metabolic benefits.
No changes in type IV collagen or FIB-4 index were observed.

Who this applies to

Adults with type 2 diabetes.
Patients diagnosed with metabolic dysfunction-associated steatotic liver disease.

Keep in Mind

The study's findings may not apply to populations outside the enrolled participants.
Effectiveness of vitamin E was not demonstrated in this study.
Further research is needed to confirm long-term benefits of dapagliflozin.

Between the Lines

Intergroup differences in liver enzyme reductions were not significant.
No changes were observed in type IV collagen levels.
The study may have limited generalizability due to specific population characteristics.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Body Composition.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

SGLT2 InhibitorsHbA1c

Medications

5 studies

Detailed evidence

SGLT2 InhibitorsBody Composition

Medications

1 studies

Detailed evidence

SGLT2 InhibitorsAdipokine and Angiogenic Markers

Medications

1 studies

Detailed evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

HbA1c Evidence Hub

All studies measuring HbA1c

5 studies

outcome_hub

Measures HbA1c as a key outcome.

SGLT2 Inhibitors Evidence Hub

All studies on SGLT2 Inhibitors

5 studies

intervention_hub

Contributes to SGLT2 Inhibitors evidence base.

Adipokine and Angiogenic Markers Evidence Hub

All studies measuring Adipokine and Angiogenic Markers

1 studies

outcome_hub

Measures Adipokine and Angiogenic Markers as a key outcome.

Body Composition Evidence Hub

All studies measuring Body Composition

1 studies

outcome_hub

Measures Body Composition as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does SGLT2 Inhibitors improve body composition?

Emerging Evidence

SGLT2 Inhibitors appears to improve Body Composition.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does SGLT2 Inhibitors improve HbA1c?

Emerging Evidence

SGLT2 Inhibitors may improve HbA1c.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 60.1 | moderate positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does SGLT2 Inhibitors affect body mass index?

Emerging Evidence

SGLT2 Inhibitors may improve Body Mass Index.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 48.4 | moderate positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

Only a small number of supporting studies are available.
Population details are unavailable.

View Full Evidence

Does SGLT2 Inhibitors improve adipokine and angiogenic markers?

Emerging Evidence

SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
LDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
2
Alanine Aminotransferase (ALT)
EvidenceScore™ Emerging | EvidenceScore™ 47.1 | moderate positive | ConsensusScore™ Mixed | 1 study

Why this answer: This answer is based on 4 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Weight Loss Evidence Hub HbA1c Reduction Evidence Hub SGLT2 Inhibitors Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Dapagliflozin and Alanine Aminotransferase (ALT)All studies on Dapagliflozin and AST All studies on Dapagliflozin and FIB-4 index All studies on Dapagliflozin and Serum γ-GT

Related research

Read related research summaries.

Dapagliflozin may improve RAAS markers in diabetes patients Dapagliflozin shows no long-term harm to bone health in women with diabetes Dapagliflozin-linagliptin combo improves glycemic control and organ protection Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes Dapagliflozin improves brain function in type 2 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.